华仁药业
(300110)
| 流通市值：39.32亿 | | | 总市值：39.37亿 |
| 流通股本：11.81亿 | | | 总股本：11.82亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 623,896,434.45 | 303,472,326.57 | 1,353,161,818.05 | 1,073,621,963.53 |
| 营业收入 | 623,896,434.45 | 303,472,326.57 | 1,353,161,818.05 | 1,073,621,963.53 |
| 二、营业总成本 | 580,297,334.96 | 281,164,064.61 | 1,270,221,916.92 | 963,605,145.6 |
| 营业成本 | 388,481,128.59 | 193,321,530 | 876,827,399.28 | 686,062,998.89 |
| 税金及附加 | 10,593,727.41 | 5,807,361.63 | 23,006,253 | 16,729,467.9 |
| 销售费用 | 83,111,639.18 | 31,407,185.48 | 141,719,328.05 | 97,292,239.84 |
| 管理费用 | 44,679,018.12 | 22,566,975.77 | 101,527,341.14 | 70,658,208.71 |
| 研发费用 | 29,961,200.24 | 14,463,043.18 | 72,290,945.17 | 49,578,277.19 |
| 财务费用 | 23,470,621.42 | 13,597,968.55 | 54,850,650.28 | 43,283,953.07 |
| 其中:利息费用 | 21,235,172.89 | 11,207,061.64 | 54,316,994.26 | 40,691,109.84 |
| 其中:利息收入 | 239,406.96 | 137,696.69 | 929,470.83 | 525,294.73 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 2,298,173.26 | -24,361.99 | -1,168,022.14 | 356,758.99 |
| 资产处置收益 | 0 | - | 16,471.15 | 5,673.96 |
| 资产减值损失(新) | -1,112,415.07 | -1,077,971.49 | -96,215,281.19 | -1,451,480.86 |
| 信用减值损失(新) | -10,469,832.22 | -6,998,760.8 | -1,352,920,181.36 | -913,335.01 |
| 其他收益 | 7,523,266.03 | 3,055,811.34 | 14,355,568.1 | 8,866,179.69 |
| 四、营业利润 | 41,838,291.49 | 17,262,979.02 | -1,352,991,544.31 | 116,880,614.7 |
| 加:营业外收入 | 2,149,924.94 | 2,118,208.88 | 127,503.15 | 582,194.48 |
| 减:营业外支出 | 1,140,657.34 | 1,123,891.84 | 2,890,089.65 | 3,052,073.1 |
| 五、利润总额 | 42,847,559.09 | 18,257,296.06 | -1,355,754,130.81 | 114,410,736.08 |
| 减:所得税费用 | 3,682,578.47 | 1,710,667.02 | 7,078,043.06 | 13,939,611.92 |
| 六、净利润 | 39,164,980.62 | 16,546,629.04 | -1,362,832,173.87 | 100,471,124.16 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 39,164,980.62 | 16,546,629.04 | -1,362,832,173.87 | 100,471,124.16 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 37,332,883.17 | 16,028,449.64 | -1,368,478,968.49 | 95,530,954.43 |
| 少数股东损益 | 1,832,097.45 | 518,179.4 | 5,646,794.62 | 4,940,169.73 |
| 扣除非经常损益后的净利润 | 27,689,155.59 | 12,256,358.34 | -1,378,192,034.43 | 89,977,848.85 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.03 | 0.01 | -1.16 | 0.08 |
| (二)稀释每股收益 | 0.03 | 0.01 | -1.16 | 0.08 |
| 九、综合收益总额 | 39,164,980.62 | 16,546,629.04 | -1,362,832,173.87 | 100,471,124.16 |
| 归属于母公司股东的综合收益总额 | 37,332,883.17 | 16,028,449.64 | -1,368,478,968.49 | 95,530,954.43 |
| 归属于少数股东的综合收益总额 | 1,832,097.45 | 518,179.4 | 5,646,794.62 | 4,940,169.73 |
| 公告日期 | 2025-08-16 | 2025-04-23 | 2025-04-23 | 2024-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |